-
Just when HIV/AIDS groups have adjusted to flat domestic HIV/AIDS funding for the past five years, the latest budget proposals arouse fear of budget cuts that could result in fewer prevention programs and longer waiting lists for antiretroviral drugs.
-
Nearly 1,000 people were on waiting lists for AIDS Drug Assistance Programs (ADAPs) at the beginning of 2006, and this number is expected to jump at least 10% when the 118 people who receive medication through the Presidents ADAP Initiative join the ranks since the initiatives funding ran out in March.
-
Sixteen HIV-infected men who have sex with men (MSM), recruited from a Seattle cohort for a study about HIV and anal dysplasia, reported having long-term sexual partners, says Mary Campbell, MD, a senior fellow in infectious diseases at the University of Washington in Seattle.
-
Below is contextual information regarding the design of proposed studies to support marketing approval of Over-the-Counter (OTC) home-use HIV test kits which includes an historical overview of rapid HIV test kit approval in the United States, and key issues for consideration by the FDA Blood Products Advisory Committee.
-
A new study has found a rising HIV prevalence rate in the border town of Tijuana, Mexico, and researchers say this could be the start of a disturbing trend.
-
One in six global AIDS deaths and one in seven new HIV infections worldwide are among children under age 15, Also, an estimated 15 million children are orphans because of AIDS, and in sub-Saharan Africa, this number is expected to rise to 18 million orphans by 2010.
-
Collaborators from the Armed Forces Research Institute for Medical Sciences (AFRIMS) and the Kwai River Christian Hospital assessed the causes of febrile illness in the adult population in Sangkhlaburi, Thailand, near the border with Myanmar.
-
Treatment of Benign Prostatic Hyperplasia; Treatment of Osteoarthritis of the Knee; Refractory Asthma and TNFConnection?; FDA Actions
-
-
Potential new uses of rifaximin are examined in a recent CID article by Adachi and DuPont. Rifaximin, a semisynthetic derivative of rifamycin, received FDA approval in May of 2004, for the treatment of travelers diarrhea in patients 12 years of age and older caused by non-invasive strains of E. coli.
